Parkinson's disease is the third most common neurological disorder. Ropinirole 4-(2-(di-n-propylamino)ethyl)-1, 3-dihydro-2H-indol-2-one, monohydrochloride is a dopamine agonist that has been recently introduced into Parkinson's disease therapy (1). Ropinirole dose is tritrated for each patient in a stepwise procedure (2). An initial oral dose of 0.25 mg/8h is maintained for a week. Then, it is slowly increased in weekly increments of 0.75 mg a day until a satisfactory clinical response is observed (usually around 3-9 mg/day).
展开▼
